Nov 07, 2024 / 09:00AM GMT
Sofia Heigis - Oncopeptides AB - Chief Executive Officer, Managing Director - Tyskland
Hi everyone and welcome to this presentation of our report for the third quarter of 2024. This is our standard disclaimer. As always, I have Henrik Bergentofts with me who will give a financial update before that I will go over some key points for the third quarter.
I will then come back with an update of our European commercialization and provide a deep dive on our three key markets in Europe, Germany including Austria, Spain and Italy. Starting off with some key highlights. The revenue in Q3 was SEK8.5 million. A slight increase versus Q2 and without a milestone payment from SCBIO for South Korea.
European sales in third quarter are slightly lower than in the second quarter, which in turn showed a 60% increase over Q1. We do see a strong start in Spain where we during this quarter have broad and regional access. Year-to-date we have unlocked 80% of the regions which we are pleased with. The speed we are moving with is due to a high unmet need for CapEx and a function of the positive clinical
Q3 2024 Oncopeptides AB Earnings Call Transcript
Nov 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers